Tetraphase Pharmaceuticals, Inc. (TTPH)

[Schnauzer1]

The bigger the problem of drug resistance bugs become, the more successful the launch of ervicycline will be in 2017-18. It's important to understand a very fine detail: ervicycline will become drug of first choice since it is effective against all the resistant bugs (except one) and it will likely have an oral formulation. All the drugs currently in P3 will become a drug of last choice because they are effective against limited number of bugs, and will require three IV injections per day.

This fine detail gives a market availability of many billions of dollars. Therefore, E could become a multi-billion dollar drug in its first year! That could push the stock price into the hundred X dollar range. I am buying more.